Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update
Current Treatment Options in Oncology · 2024
DOI: 10.1007/s11864-024-01272-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Chunxiao He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. hechx26@mail.sysu.edu.cn. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Mutation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shenzhen Science and Technology Innovation Commission.
Abstract (Originalsprache)
OPINION STATEMENT: Gastrointestinal stromal tumor (GIST) is characterized by well-defined oncogenes. Despite the significant improvement in treatment outcomes with adjuvant imatinib therapy for patients, drug resistance remains a major challenge for GIST therapy. This review focuses on the mechanisms contributing to drug resistance phenotype in GIST, such as primary imatinib-resistant mutants, secondary mutations, non-covalent binding of TKI to its target, tumor heterogeneity, re-activation of pro-survival/proliferation pathways through non-KIT/PDGFRA kinases, and loss of therapeutic targets in wild-type GIST. Corresponding suggestions are proposed to overcome drug-resistance phenotype of GIST. This review also summarizes the suitability of currently approved TKIs on different KIT/PDGFRA mutations and updates related clinical trials. Recent potent drugs and emerging strategies against advanced GISTs in clinical trials are presented. Additionally, metabolic intervention offers a new avenue for clinical management in GIST. A landscape of metabolism in GIST and metabolic changes under imatinib treatment are summarized based on currently published data. The OXPHOS pathway is a promising therapeutic target in combination with TKI against sensitive KIT/PDGFRA mutants. Comprehensive understanding of the above resistance mechanisms, experimental drugs/strategies and metabolic changes is critical to implement the proper therapy strategy and improve the clinical therapy outcomes for GIST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. hechx26@mail.sysu.edu.cn.
- The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
- Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.
- Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. xiangx25@mail.sysu.edu.cn.
Förderung
- Shenzhen Science and Technology Innovation Commission
Zitieren
APA
He, C., Wang, Z., Yu, J., Mao, S., & Xiang, X. (2024). Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01272-7
Vancouver
He C, Wang Z, Yu J, Mao S, Xiang X. Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01272-7
BibTeX
@article{He2024,
author = {He, Chunxiao and Wang, Zilong and Yu, Jiaying and Mao, Shuang and Xiang, Xi},
title = {Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update},
journal = {Current Treatment Options in Oncology},
year = {2024},
doi = {10.1007/s11864-024-01272-7}
}
EUVIMED